A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) Administered Subcutaneously to Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)

The current clinical trial is evaluating a potential treatment to reduce plasma Lp(a) levels in patients with hyperlipoproteinemia(a) and established cardiovascular disease. It is a randomized, double-blind, placebo-controlled study, meaning participants and researchers are not aware of who is receiving the treatment. There also will be a placebo group that is not receiving the treatment although five out of six patients randomized will receive the drug at some dose.


Anna Tran atran@bcm.eduPhone 1: (713) 798-3957
IRB: h-40320




Oct 03, 2017